TC
CTMX icon

Tejara Capital’s CytomX Therapeutics CTMX Stock Holding History

Tejara Capital’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-157,928
Closed -$238K – 83
2023
Q1 		$238K Sell
157,928
-78,122
-33% -$177K 0.12% 74
2022
Q4 		$378K Buy
+236,050
New +$349K 0.22% 71

Other funds holding CTMX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Tejara Capital's CTMX Position: Q2 2023 in Review

Tejara Capital sold out of CytomX Therapeutics (CTMX) in Q2 2023, closing a stake of 157,928 shares — an estimated $238K sold.

Tejara Capital first reported a position in CTMX in Q4 2022 and held it in 2 quarters. The position peaked at $378K in Q4 2022. 67 funds tracked by Wall St. Rank hold CTMX as of Q2 2023.

  • Tejara Capital reported no remaining CytomX Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Tejara Capital sold 157,928 CytomX Therapeutics shares in Q2 2023, an estimated $238K.
  • Tejara Capital first reported a position in CytomX Therapeutics in Q4 2022 and held it in 2 quarters.
  • Tejara Capital's CytomX Therapeutics position peaked at $378K in Q4 2022.
  • 67 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2023.

Based on Tejara Capital's 13F filing for Q2 2023, filed 11 Aug 2023.